Alice Zerbinati: Y-90 Radioembolization Expands Curative Options for Advanced Hepatocellular Carcinoma
Alice Zerbinati, Senior Medical Education and Affairs Manager at TheraSphere EMEA, shared Arndt Vogel’s post on LinkedIn about a recent article by Carlo Sposito et al, published in Hepatology, adding:
“Should portal vein tumor thrombosis PVT automatically exclude patients from curativeintent treatment?
For patients with HCC and PVT, the answer has often been yes.
Limited options. Poor prognosis. Few opportunities to reach potentially curative therapies.
Studies like this challenge us to think differently.
This multicenter Italian experience shows that, in selected patients, Y90 radioembolization can successfully downstage unlocking access to liver transplantation, offering a chance that would have been considered out of reach for many patients.
What stands out to me is not only the clinical outcome, but the power of #multidisciplinary collaboration.
Hepatologists, transplant surgeons, interventional radiologists, nuclear medicine physicians, and oncologists working together to reassess what is possible for advanced HCC patients.
Congratulations to all authors for this important contribution to the evolving HCC treatment landscape.”
Arndt Vogel, Professor at Toronto General Hospital, shared a post on LinkedIn:
“Outcomes of Y90-radioembolization as downstaging to liver transplantation HCC and tumoral portal vein thrombosis.
25 percent sustained downstaging after TARE.
15 percent eventually LTx with good outcome.
Downstaging is feasible in MVI pts.”
Title: Outcomes of Y90-radioembolization as downstaging to liver transplantation in patients with hepatocellular carcinoma and tumoral portal vein thrombosis
Authors: Carlo Sposito, Giammauro Berardi, Mauro Viganò, Matteo Serenari, Chiara Mazzarelli, Monica Paoletti, Edoardo Maria Muttillo, Massimo De Giorgio, Cristina Mosconi, Marco Solcia, Carlo Chiesa, Luca S Belli, Matteo Cescon, Stefano Fagiuoli, Rodolfo Lanocita, Laura Crocetti, Giuseppe M Ettorre, Vincenzo Mazzaferro
Stay updated on all scientific advances with Hemostasis Today.
-
Jun 7, 2026, 12:01Addressing Real-World Challenges in Thrombosis Care Through Case-Based Learning – Thrombosis Canada
-
Jun 7, 2026, 11:46Zehraan Ibni Akbar: Transforming Laboratory Data into Clinical Decisions Through Platelet Disorder Recognition
-
Jun 7, 2026, 09:26Filimon Dagnew Bezabih: SNMMI Honors 18F-GP1 PET Imaging for Innovation in Thrombosis Detection
-
Jun 7, 2026, 06:57Chandran Nadarajan: Targeted Endovascular Thrombolysis Offers Organ-Saving Benefits in Vascular Occlusions
-
Jun 7, 2026, 05:50Sayan Koley: Lupus Anticoagulant – A Key Marker in Thrombosis Risk Assessment
-
Jun 7, 2026, 05:45Nicolas Hubacz: Watching a Heart Build Its Network
-
Jun 7, 2026, 05:40New Evidence Highlights the Urgent Need for Gender-Inclusive Bleeding Disorders Research – EHC
-
Jun 7, 2026, 03:15Shirley D’Sa: What Comes After BTK Inhibitors in Waldenström Macroglobulinaemia?
-
Jun 6, 2026, 23:30Yazan Abou-Ismail: Insights on A Snail-Derived Potential Anticoagulant with Possibly Improved Bleeding Profile